2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
3
Breast Neoplasms
3
Sarcoma, Synovial
2
Recurrence
2
Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Lymphoma
2
Liposarcoma, Myxoid
2
Hodgkin Disease
2
Graft vs Host Disease
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Interventions
Temozolomide
163
Radiosurgery
129
Radiotherapy
107
Bevacizumab
98
Magnetic Resonance Spectroscopy
75
Carboplatin
48
Surgical Procedures, Operative
35
pembrolizumab
34
Radiation
34
Etoposide
34
Nivolumab
33
Irinotecan
33
Cyclophosphamide
33
Erlotinib Hydrochloride
31
Carmustine
28
Lomustine
26
Trastuzumab
25
Cisplatin
25
Ipilimumab
24
Filgrastim
23
Mental Status and Dementia Tests
21
Magnetic Resonance Imaging
21
Aminolevulinic Acid
21
Vincristine
20
Surveys and Questionnaires
19
Capecitabine
19
Topotecan
18
Specimen Handling
18
Pemetrexed
18
Radiotherapy, Intensity-Modulated
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
Interferon-gamma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled